BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1729 related articles for article (PubMed ID: 8596936)

  • 1. Enhancement of antitumor immunity by CTLA-4 blockade.
    Leach DR; Krummel MF; Allison JP
    Science; 1996 Mar; 271(5256):1734-6. PubMed ID: 8596936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD28-independent costimulation of T cells in alloimmune responses.
    Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
    J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
    Chen L; Ashe S; Brady WA; Hellström I; Hellström KE; Ledbetter JA; McGowan P; Linsley PS
    Cell; 1992 Dec; 71(7):1093-102. PubMed ID: 1335364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complexity of the B7-CD28/CTLA-4 costimulatory pathway.
    Schweitzer AN; Sharpe AH
    Agents Actions Suppl; 1998; 49():33-43. PubMed ID: 9426826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of B7-dependent responses in CD28-deficient mice.
    Green JM; Noel PJ; Sperling AI; Walunas TL; Gray GS; Bluestone JA; Thompson CB
    Immunity; 1994 Sep; 1(6):501-8. PubMed ID: 7534617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
    Wu Y; Guo Y; Huang A; Zheng P; Liu Y
    J Exp Med; 1997 Apr; 185(7):1327-35. PubMed ID: 9104819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Yin and Yang of T cell costimulation.
    Allison JP; Krummel MF
    Science; 1995 Nov; 270(5238):932-3. PubMed ID: 7481795
    [No Abstract]   [Full Text] [Related]  

  • 9. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.
    LaBelle JL; Hanke CA; Blazar BR; Truitt RL
    Blood; 2002 Mar; 99(6):2146-53. PubMed ID: 11877291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients.
    Pistillo MP; Tazzari PL; Bonifazi F; Bandini G; Kato T; Matsui T; Nishioka K; Conte R; Ferrara GB
    Transplantation; 2002 Apr; 73(8):1295-302. PubMed ID: 11981425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.
    Krummel MF; Sullivan TJ; Allison JP
    Int Immunol; 1996 Apr; 8(4):519-23. PubMed ID: 8671638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice.
    Sabel MS; Hess SD; Egilmez NK; Conway TF; Chen FA; Bankert RB
    Cancer Immunol Immunother; 2005 Oct; 54(10):944-52. PubMed ID: 15846492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD28/B7 costimulation: a review.
    Greenfield EA; Nguyen KA; Kuchroo VK
    Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costimulatory regulation of T cell function.
    Chambers CA; Allison JP
    Curr Opin Cell Biol; 1999 Apr; 11(2):203-10. PubMed ID: 10209159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.
    Freeman GJ; Borriello F; Hodes RJ; Reiser H; Hathcock KS; Laszlo G; McKnight AJ; Kim J; Du L; Lombard DB
    Science; 1993 Nov; 262(5135):907-9. PubMed ID: 7694362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

  • 18. Tuning tumor-specific T-cell activation: a matter of costimulation?
    Abken H; Hombach A; Heuser C; Kronfeld K; Seliger B
    Trends Immunol; 2002 May; 23(5):240-5. PubMed ID: 12102744
    [No Abstract]   [Full Text] [Related]  

  • 19. The ups and downs of T cell costimulation.
    Jenkins MK
    Immunity; 1994 Sep; 1(6):443-6. PubMed ID: 7534615
    [No Abstract]   [Full Text] [Related]  

  • 20. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody.
    Vanhove B; Laflamme G; Coulon F; Mougin M; Vusio P; Haspot F; Tiollier J; Soulillou JP
    Blood; 2003 Jul; 102(2):564-70. PubMed ID: 12649149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 87.